Holen Sie sich die Stockscreener-App
1.38
0.72%
-0.01
Vorhandelsmarkt:
1.37
-0.010
-0.72%
Schlusskurs vom Vortag:
$1.39
Offen:
$1.39
24-Stunden-Volumen:
608.03K
Relative Volume:
0.52
Marktkapitalisierung:
$142.42M
Einnahmen:
$32.29M
Nettoeinkommen (Verlust:
$-39.12M
KGV:
-3.7612
EPS:
-0.3669
Netto-Cashflow:
$-29.51M
1W Leistung:
-0.72%
1M Leistung:
+17.95%
6M Leistung:
+86.64%
1J Leistung:
-0.72%
1-Tages-Spanne:
$1.36
$1.405
1-Wochen-Bereich:
$1.26
$1.407
52-Wochen-Spanne:
$0.6434
$1.865
Maxcyte Inc Stock (MXCT) Company Profile
Firmenname
Maxcyte Inc
Sektor
Branche
Telefon
301-517-5556
Adresse
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
1.38 | 143.46M | 32.29M | -39.12M | -29.51M | -0.3669 |
ABT
Abbott Laboratories
|
114.14 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
327.70 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.30 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.37 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.83 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-08-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-07-22 | Eingeleitet | Stephens | Overweight |
| 2023-11-29 | Eingeleitet | Craig Hallum | Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | BTIG Research | Buy |
| 2021-08-24 | Eingeleitet | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | Stephens | Overweight |
| 2021-08-24 | Eingeleitet | Stifel | Buy |
| 2021-08-24 | Eingeleitet | Wedbush | Outperform |
| 2021-08-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Maxcyte Inc Aktie (MXCT) Neueste Nachrichten
MaxCyte (MXCT) Q2 2026 Earnings: EPS Comes in Above Forecast in the Latest Reading; Market Reaction - Vinanet
MaxCyte Gets A Genentech Nod, But Revenue Still Comes In Chunks - Finimize
MaxCyte launches base editor off-target nomination assays By Investing.com - Investing.com Nigeria
MaxCyte (MXCT) Earnings Reading: EPS Prints Above Forecast in the Latest Session; Stock Move - Vinanet
MaxCyte launches base editor off-target nomination assays - Investing.com
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies - The Manila Times
MaxCyte launches a gene-editing test that sees population-specific DNA variants - Stock Titan
MaxCyte, Inc. Revenue Breakdown – NASDAQ:MXCT - TradingView
MaxCyte(MXCT) Stock Options Chain | Quotes & News - Moomoo
MXCT Q2 2026 Earnings: Narrower-Than-Expected Loss Marks a 15.97% EPS Beat, Yet Shares Slip 5.04%Earnings Sentiment Score - Vinanet
Teleconferência de Resultados do 2T26 da MaxCyte (MXCT): Guidance Reafirmado com a Expansão da Parceria com a Genentech - TradingKey
MaxCyte Inc (NASDAQ: MXCT) Stock Price, News & Analysis - Kalkine
Conferencia de resultados del T2 de 2026 de MaxCyte (MXCT): Se reafirman las proyecciones a medida que se amplía la alianza con Genentech - TradingKey
MaxCyte, Inc. Releases Q2 2026 Results: Cell Engineering Platform Momentum in FocusPerformance Review - Vinanet
MaxCyte (MXCT) Earnings Call Q2 2026: Prognose bekräftigt bei Ausbau der Genentech-Partnerschaft - TradingKey
MaxCyte (MXCT) Q2 2026 Earnings Call: Guidance Reaffirmed as Genentech Partnership Expands - TradingKey
MaxCyte (MXCT) Stock Price Reflects Faith In Royalties Over Core Weakness - Sahm
TD Cowen Maintains MaxCyte(MXCT.US) With Buy Rating - Moomoo
MaxCyte revenue down 15% to USD 7.3M in Q2 2026 - Medical Buyer
MaxCyte, Inc. $MXCT Shares Acquired by Renaissance Technologies LLC - MarketBeat
Price to sales forward of MaxCyte, Inc. – MUN:MYE0 - TradingView
MaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ... - Yahoo! Finance Canada
MXCT Looks 49.6% Undervalued on GF Value™ - GuruFocus
MaxCyte, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
MaxCyte Q2 Earnings Call Highlights - MarketBeat
MaxCyte (NASDAQ:MXCT) Issues Earnings Results - MarketBeat
MaxCyte affirms FY26 sales guidance of $30M-$32M vs estimate - scanx.trade
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings call transcript: MaxCyte tops Q2 2026 revenue forecast, shares fall - Investing.com
MaxCyte Reports Q2 Results, Highlights Genentech Partnership - TipRanks
MaxCyte Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Maxcyte, Inc. Provides Earnings Guidance for the Back Half of 2026 and Reiterates Earnings Revenue Guidance for the Full Year 2026 - marketscreener.com
Tranche Update on MaxCyte, Inc.'s Equity Buyback Plan announced on May 12, 2026. - marketscreener.com
MaxCyte Reports Second Quarter 2026 Financial Results - The Manila Times
MXCT Q1 2026 Earnings: EPS Surprise of 50.98% Delivers Narrower Loss, Shares Rise 2.48%Earnings Analysis - Vinanet
RIVER GLOBAL INVESTORS LLP Trims MaxCyte Inc (MXCT) Stake -- Shares Trade at 52% Discount to GF Value - GuruFocus
MaxCyte Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
MaxCyte (MXCT) Q1 2026 Earnings: Narrower Loss Beats Estimates as Shares Rise 6.31%Financial Summary - dars.gov.et
MaxCyte (MXCT) Climbs 6.3% to $1.18 as Cell Engineering Momentum BuildsOvernight Profile - Vinanet
Earnings Preview: MaxCyte to Report Financial Results Post-market on August 12 - Moomoo
MaxCyte | 4: Statement of changes in beneficial ownership of securities-Director Johnston John Joseph - Moomoo
Latest MXCT ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
MaxCyte (MXCT) Expected to Post Earnings on Wednesday - MarketBeat
River Global Investors Discloses Investment at MaxCyte with 0.78% Stake - TradingView
MaxCyte, Inc. (MXCT) holder River Global shifts 4.3% voting stake - Stock Titan
MXCT Q1 2026 Earnings: Narrower-Than-Expected Loss Drives 50.98% EPS SurpriseOperating Income Trends - Vinanet
MXCT Q1 2026 Earnings: Narrower Loss of -$0.04 per Share Beats Estimates Despite Missing Revenue DisclosureFinal Results - Vinanet
BlackRock (MXCT holder) discloses 1,402,591 MaxCyte shares, a 1.3% ownership stake - Stock Titan
MXCT Q1 2026 Earnings: EPS Beats Estimates but Shares DipMid-Term Outlook - Vinanet
MaxCyte Inc (MXCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MaxCyte Inc (MXCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Finanzdaten der Maxcyte Inc-Aktie (MXCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.76%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):